El.En. S.p.A. · MIL:ELN

El.En — Banca IFIGEST (June 2011)

38 slides from El.En's conference presentation, Jun 24, 2011

  1. Slide 1: Company Presentation

    BANCA IFIGEST June 24th , 2011 Company Presentation

  2. Slide 2: Disclaimer

    Disclaimer Certain statements in this slide show, including those addressing the Company’s beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward‐looking statements. Forward‐looking statements involve known or unknown risks, including general economic

  3. Slide 3: Summary

    Summary 1. THE GLOBAL LASER MARKET 2. EL.EN. GROUP 3. 2010 FINANCIAL RESULTS 4. Q1‐2011 FINANCIAL RESULTS 5. 2011 GUIDANCE

  4. Slide 4: The Global Laser Market

    The Global Laser Market

  5. Slide 5: LASER

    LASER Light Amplification Stimulated by Emission of Radiation LASER Sources (Laser beam generator) LASER Systems (Manage laser beam energy to perform several applications)

  6. Slide 6: The Laser Market - Total: $6.37 Billion

    The Laser Market ‐ Total: $6.37 Billion Instrumentation andImage recording LASER Sources Scentific and military sensor Pumps 1% Entertainement and 4% 3% display 6% ONLY Data storage 0% 13% Industrial proces 35% Communications Medical and 31% aesthetic 7% Industrial Processing $ 2,2 B Medical and Aes

  7. Slide 7: El.En.: Trademarks and Markets

    El.En.: Trademarks and Markets MEDICAL INDUSTRIAL

  8. Slide 8: The Medical Laser Market

    The MEDICAL Laser Market Medical w\o diagnostic: CAGR 13,3% Surgical, Aesthetic, Ophthalmic, Therapeutic, Service and Accessories 2008 2009 $2,3B $1,9B Medical w\o diagnostic (Therapeutic) expected to grow to $3,7B in 2014 El.En. medical revenues (FY2010) are 65% of consolidated sales Source: BCC Re

  9. Slide 9: The Aesthetic Laser Market

    The AESTHETIC Laser Market CAGR 12,3% CAGR 12,4% 1) Aesthetic products market (including cosmetics products) is expected to grow by 12.3% @ $6.8 B 2) The skin tightening and body shaping systems market is expected to grow at the same rate, however average product prices are much higher in this segme

  10. Slide 10: The Aesthetic Laser Market Shares

    The AESTHETIC Laser Market Shares Revenues in $ M 2008 2009 2010 El.En. Aesthetic/Medical $ 97.4 $ 72.8 $ 89.9 Cynosure $ 139.0 $ 72.5 $ 81.5 Peer group Total $ 860.7 $ 617.7 $ 683.7 % El.En. 11.3% 11.8% 13.1% % Cyno 16.2% 11.7% 11.9% % El.En. Group (*) 27.5% 23.5% 25.1% (*) market share calculation

  11. Slide 11: The Industrial Laser Market

    The INDUSTRIAL Laser Market Laser Sources Market Revenues ($M) Laser Systems Manufacturers Revenues ($M) 2008 2009 2010 Rofin Sinar $575 $349 $423 IPG $229 $185 $299 Coherent $599 $435 $605 Prima Industrie $477 $300 $325 Trumpf AG $2.161 $1.742 $2.174(*) Total $4.041 $3.011 $3.826 % YoY Change ‐25,5

  12. Slide 12: Strategic Strengths

    Strategic Strengths Multidisciplinary and multifacility R&D activity: sources, systems, applications. Covering both Medical and Industrial laser markets Industrial Combine High tech laser source development with flexible production facilities in high growth areas Medical Maximize market penetratio

  13. Slide 13: El.En. Group

    El.En. Group

  14. Slide 14: Group Overview

    Group Overview High ‐Tech Industrial Group Develops, manufactures and distributes laser sources and laser systems for medical and industrial applications Know‐how based on stratification of 30 years of multidisciplinary experience 2010 Consolidated Revenues of €190 mln, up 27% YoY 969 employees Glob

  15. Slide 15: Yearly Consolidated Revenues and EBIT

    Yearly Consolidated Revenues and EBIT (*) EBIT 2006 w/o the one time $10M change Cynosure/Palomar

  16. Slide 16: R&D Activity

    R&D Activity Clinical trials and validations of new therapeutic laser treatments and research on new applications of laser‐ tissue interaction Laser systems for regenerative medicine Laser and ultrasound combination systems for minimally invasive surgery Development of new cutting edge CO2 platform

  17. Slide 17: R&D expenses as of Dec. 31st, 2010

    R&D expenses as of Dec. 31st, 2010 31/12/09 31/12/10 Var.% R&D expenses 11,381 12,333 8.4% Percentage on group revenues 8% 6% Grants 1,138 1,018 ‐10.5%  100 Researchers  5 R&D labs: Florence, Milan, Naples, Jena, Boston

  18. Slide 18: Medical/Aesthetic

    Medical/Aesthetic Aesthetic Medical Hair Removal ENT Vascular Lesions Gynaechology Skin Rejuvenation Urology Pigmented Lesions Endovascular Treatment of Cellulite Onchology Acne Dermatology Tattoo Removal Psoriasis and Vitiligo Anti ‐ Aging Dentistry LaserBody Sculpting Therapy Removal of Unwanted F

  19. Slide 19: Cynosure

    Cynosure 2002 70 % Acquisition share price $3,5 2003‐2004 Turnaround 2005 Nasdaq IPO, share price $ 15 holding down to 35% 2007 Stock sale, share price $ 29 holding down to 23% Control and consolidation allowed by a statutory clause

  20. Slide 20: Cynosure

    Cynosure Strategic cooperation R&D Smartlipo MPX – Triplex ‐ Cellulaze Distribution Smartlipo ‐ Fractional CO2 – Tattoo Removal 2008 2009 2010 Sales of ex Cyno El.En. group to 12,560 4,369 4,163 Cynosure (Euro 000) % on ex Cyno Aesthetic sales 16.80% 7.80% 6.00%

  21. Slide 21: Cynosure

    Cynosure USD +12% +12% ‐14% ‐14% +17% +17%

  22. Slide 22: Medical Laser: Breakdown by Area

    Medical Laser: Breakdown by Area Europe 51 32 37 Far East 65 USA 2008 2009 2010 41 31 30 30 24 Italy 2008 2009 2010 2008 2009 2010 15 11 13 2008 2009 2010

  23. Slide 23: Industrial Laser: Breakdown by Area

    Industrial Laser: Breakdown by Area Europe 9 3 5 Am erica 2008 2009 2010 Far East 6 4 3 11 Italy 4 5 2008 2009 2010 11 8 8 2008 2009 2010 2008 2009 2010

  24. Slide 24: 2010 Financial Results

    2010 Financial Results

  25. Slide 25: Consolidated P&L - FY2010

    Consolidated P&L – FY2010 31/12/09 31/12/10 Var.% Revenues 149,111 100.0% 189,797 100.0% 27.3% Gross margin 79,287 53.2% 100,448 52.9% 26.7% EBITDA (4,026) ‐2.7% 14,297 7.5% EBIT (12,598) ‐8.4% 5,422 2.9% Income before taxes (12,331) ‐8.3% 4,689 2.5% Net Income (Loss) (5,258) ‐3.5% 1,268 0.7% 31/12/

  26. Slide 26: Consolidated BS - FY2010

    Consolidated BS – FY2010 31/12/09 31/12/10 Var. Goodwill 5,881 6,089 208 Tangible and Intangible assets 30,939 29,979 ‐960 Other non current assets 9,385 13,858 4,472 Total non current assets 46,205 49,925 3,720 Inventory 50,531 55,650 5,119 Accounts receivables 36,573 46,714 10,142 Other short‐term

  27. Slide 27: Consolidated P&L - FY2010 (w/o Cynosure)

    Consolidated P&L – FY2010 (w/o Cynosure) 31/12/09 31/12/10 Var.% Revenues 101,764 100.0% 132,566 100.0% 30.3% Gross margin 50,325 49.5% 67,076 50.6% 33.3% EBITDA 2,282 2.2% 13,327 10.1% 484.1% EBIT (1,454) ‐1.4% 8,361 6.3% Income before taxes (2,016) ‐2.0% 7,697 5.8% Net Income (Loss) (3,071) ‐3.0%

  28. Slide 28: El.En. - Revenues breakdown by business

    El.En. – Revenues breakdown by business El.En +30% Cutting Marking Laser sources +54% Medical +18% Industrial +27% Aesthetic Surgical CO2 Physiotherapy Dental Cynosure Q1-2011: +9% Medical Aesthetic Service

  29. Slide 29: El.En. - Medical and Aesthetic Sector

    El.En. – Medical and Aesthetic Sector El.En Industrial FY 2010: + 27% 4.673 11.141 Service % + 28 4.594 Medical 3.651 % +37 % 8.119 +19 Accessories 3.866 Other Medical Lasers 48.728 + 30 % Dental 35.900 Aesthetic 4.447 +8% 4.798 Physiotherapy +16% 8.495 9.831 Surgical CO2 December 31st 2009 December

  30. Slide 30: El.En. - Industrial Sector

    El.En. – Industrial Sector El.En Industrial FY 2010: + 54% Other 2.102 5% 4.170 Brazil +2 % China 02 +1 1.681 10.436 Europe 2.062 +164% Italy 3.947 3.302 +44% 4.763 Service ‐2% 8.191 7.992 Medical December 31st 2009 December 31st 2010 Q1-2011: +56% Cynosure Medical Aesthetic Service

  31. Slide 31: Q1-2011 Financial Results

    Q1 ‐ 2011 Financial Results

  32. Slide 32: Consolidated P&L Q1-2011

    Consolidated P&L Q1‐2011 31/03/10 31/03/11 Var.% unaudited unaudited Revenues 41,061 100.0% 45,338 100.0% 10.4% Gross margin 21,927 53.4% 24,640 54.3% 12.4% EBITDA 1,377 3.4% 2,130 4.7% 54.7% EBIT (492) ‐1.2% (470) ‐1.0% ‐4.5% Income before taxes (433) ‐1.1% (1,308) ‐2.9% 202.0% 31/12/10 31/03/11 Ne

  33. Slide 33: Consolidated P&L Q1-2011 (w/o Cynosure)

    Consolidated P&L Q1‐2011 (w/o Cynosure) 31/03/10 31/03/11 Var.% unaudited unaudited Revenues 28,397 100.0% 30,885 100.0% 8.8% Gross margin 14,220 50.1% 16,228 52.5% 14.1% EBITDA 1,695 6.0% 2,401 7.8% 41.7% EBIT 971 3.4% 1,009 3.3% 3.9% Income before taxes 1,114 3.9% (6) 0.0% 31/12/10 31/03/11 Net fi

  34. Slide 34: 2011 Guidance

    y UO < © = S O = = © Ni

  35. Slide 35: 2010 - Out of the downturn

    2010 ‐ Out of the downturn Rapidly Industrial laser systems in China and Brazil Surgical laser systems by Quanta System Aesthetic laser systems in Europe and Far East Slowly Aesthetic laser systems in US and Spain …and investing Distribution in the US for Deka Dental and Medical Distribution i

  36. Slide 36: 2011 forecast - El.En. stand alone

    2011 forecast – El.En. stand alone 2010 2011 Var. Sales 133 Mln 146 Mln 10% EBIT % 6.3% EBIT% improvement expected

  37. Slide 37: El.En. and Cynosure stock performance

    El.En. and Cynosure stock performance 20 El.En 18 16 14 12 10 8 Q1 2009 Q2 2009 Q3 2009 Q4 2009 Q1 2010 Q2 2010 Q3 2010 Q4 2010 Q1 2011 El.En S.p.A. FTSE Italy Star Fixed Cynosure 18 16 14 12 10 8 6 4 Q1 2009 Q2 2009 Q3 2009 Q4 2009 Q1 2010 Q2 2010 Q3 2010 Q4 2010 Q1 2011 Cynosure Inc. (Cl A) NASDAQ

  38. Slide 38: El.En. SPA / Polytems HIR SRL

    El.En. SPA Enrico ROMAGNOLI Investor Relations Director tel. +39 055‐8826807 E‐mail: finance@elen.it POLYTEMS HIR SRL Bianca FERSINI MASTELLONI Financial Communication & Press office Tel. +39 06‐6797849 / +39 06‐69923324 E‐mail: b.fersini@polytemshir.it

El.En. — Banca IFIGEST (June 2011) on 6ix